Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback